Introduction L-Asparaginase is the first enzyme to be therapeutically effective in human malignant disease. Kidd (1953) found that the injection of guinea-pig serum caused pronounced regression of the mouse Gardner lymphosarcoma. Broome (1961 Broome ( , 1963 showed that guinea-pig serum was effective because of its content of asparaginase, and Old et al (1963) demonstrated an antileukaemic effect of L-asparaginase in mice. With the isolation of an active L-asparaginase from Escherichia coli by Mashburn and Wriston (1964) enough material became available for clinical trials, and a number of remissions were reported in acute lymphoblastic leukaemia (Hill et al., 1967; Oettgen et al., 1967) .
L-Asparaginase from three sources-two from E. coli (supplied by E. R. Squibb and Farbenfabriken Bayer, A. G.) and one from Erwinia carotovora (supplied by Microbiological
Research Establishment, Porton) § §-was made available and * Consultant in Haematology, St. Bartholomew's Hospital, London E.C.1. used in the treatment of acute lymphoblastic leukaemia, acute myeloid leukaemia, and lymphoblastic lymphosarcoma.
Patients Treated and Method of Administration
Twenty-three patients with acute lymphoblastic leukaemia, 11 with acute myeloid leukaemia, and six with lymphoblastic lymphosarcoma were treated with L-asparaginase. The diagnosis was based on the appearance of films of the peripheral blood and on bone marrow examinations. In the lymphosarcoma patients confirmatory lymph node biopsy specimens were obtained where necessary.
The dosage of Squibb, Bayer, or Porton L-asparaginase was kept the same for all three preparations, except in two cases. Initially a dose of 1,000 i.u./kg. of body weight daily was given but later the dose was based on surface area because it is known that the enzyme is virtually confined to the plasma (J. Hall and C. B. Cameron, personal communication, 1969) . The dose per square metre was about 35,000 i.u./day. The daily dose was divided into two halves and given intravenously every 12 hours in about 10 ml. of saline. One patient treated with the Porton enzyme received 250 i.u./kg. daily, and one treated with the Bayer enzyme received 350,000 i.u./sq. m. for the first four days. As intravenous administration is not always possible in children it may be given intramuscularly in about 4 ml. of saline.
In nearly all patients a small initial dose was given intradermally or intravenously to determine any sensitivity. One unit was followed shortly by 10 units, and then by 50 units. The full regimen was now started, being continued if possible for 28 days. The number of patients treated with each type of L-asparaginase is shown in Table I . 
Induction of Remission
The results of treatment of 15 patients in relapse are shown in Table III . (Holland et al., 1968) . The total of five complete remissions in 15 patients compares well with the proportion seen in other series (Oettgen and Schulten, 1969; Begemann, 1969) . All the patients who responded showed a very rapid disappearance of blast cells from the circulating blood, though clearance of the bone marrow usually occurred much later. An example of this is shown in Fig. 1 (Fig. 2) . The third course acted initially in the same way, but on the 17th day of treatment blast cells appeared again in the blood and rose rapidly when treatment with L-asparaginase was stopped (Fig. 3) . When, 20 days later, the leukaemic cells were tested for their sensitivity to the drug in vitro by means of the technique of Oettgen et al. (1967) , they still showed sensitivity to the action of the enzyme; after 18 hours' incubation there was a reduction of 60% in the uptake of tritiated uridine by the cells grown in a medium free from asparagine or with added asparaginase, when compared with the uptake in the medium containing asparagine. A fourth course following relapse again showed a dramatic fall in the number of blast cells, but a rapid rise again as treatment continued (Fig. 4) .
Maintenance of Remission
Of eight patients in remission who were treated with Bayer L-asparaginase, methotrexate, and folinic acid in an attempt to reduce the number of leukaemic cells still further, two had relapsed at the end of three months and four were still in Porton L-asparaginase preparations are still being purified and it is too early to assess its toxicity. The initial material caused more fever than Bayer L-asparaginase, and in Case 38 hyperglycaemia occurred. One patient, not included in this series, went into diabetic coma and required insulin. It is possible that the unexplained coma in Case 7 was also associated with hyperglycaemia, but as this complication had not been described at that time the blood glucose was not measured. This patient recovered consciousness rapidly when treatment with the enzyme was stopped.
Discussion
Using L-asparaginase alone we have had results in the treatment of acute lymphoblastic leukaemia similar to those of Schmidt and Gallmeier (1968) , Oettgen and Schulten (1969) , and Begemann (1969) . L-Asparaginase produces remission in about one-third of the patients with acute lymphoblastic leukaemia who have had previous treatment. The enzyme is ineffective when used alone in treating acute myeloid leukaemia, because of the development of resistance, but as it is not toxic to the bone marrow it may have a place concurrently and in sequence with daunorubicin, cytosine arabinoside, and mercaptopurine. When it is used in this way the early development of resistance may be minimized. McElwain and Hardisty (1969) reported encouraging results in acute lymphoblastic leukaemia in relapse when using L-asparaginase after a course of cytosine arabinoside.
A major problem in the use of L-asparaginase for the treatment of human malignant disease is the development of resistance to the enzyme. Furthermore, it is disappointing to find that though malignant cells, particularly in myeloblastic leukaemia and malignant melanoma, are sensitive to the action of the enzyme in vitro, clinical response is rare. There may be several explanations for this.
One of the most impressive effects clinically has been the rapid clearance of leukaemic cells from vthe blood but their very slow clearance from the marrow. This has been particularly noticeable in acute lymphoblastic leukaemia, where all the blast cells may disappear from the blood within 48 hours but the marrow may not remit for 21 to 28 days (as shown in Figs. 1-4) . Another interesting observation, particularly in acute myeloid leukaemia, is that the number of blast cells in the blood may fall dramatically at first but after some days reappear and even increase in number.
One reason for the rapid clearance of blast cells from the blood, but the slow clearance from the marrow, could be that after injection virtually all the enzyme remains confined to the plasma and only trivial amounts enter the interstitial fluid compartment (J. Hall and C. B. Cameron, personal communication, 1969 (Figs. 1-4 ).
For these reasons we believe that asparaginase should be used in combination with other drugs in the treatment of acute leukaemia. Although when used alone it does not produce complete remission in acute myeloid leukaemia, it still may have a part to play when used in combination, for any treatment which can reduce the number of malignant cells without harming normal haemopoietic cells may be a useful agent when combined with other drugs. The value of Lasparaginase in the treatment of malignant disease in combination with other forms of chemotherapy or radiotherapy has still to be elucidated.
